Medical Developments International Limited Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada

PICKERING, ON and VICTORIA, Australia, Sept. 11, 2016 /CNW/ - Medical Developments International Limited ("MDI") (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox^® (Low-Dose Methoxyflurane) Inhaler in Canada.   

Penthrox^® is a fast-acting, inhaled, non-narcotic analgesic drug/device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  Penthrox is approved for marketing in 15 countries (including: Australia, UK, Ireland, France and Belgium).  It has been marketed in Australia since 1975. 

The CEO of MDI, Mr. John Sharman said: "This is an exciting deal for MDI and is a critical step towards providing the Canadian healthcare system with another valuable therapeutic option for the treatment of pain. Purdue has market leading expertise in pain management products and will invest in providing the educational resources to healthcare practitioners on the appropriate use, benefits, and safety profile of Penthrox."

Dr. Craig Landau, President and CEO, Purdue Pharma (Canada) added: "Subject to regulatory approval by Health Canada, Penthrox will provide Canadian patients and ER Physicians with an important, non-opioid treatment option for medical situations involving acute trauma pain that is moderate to severe in nature. Penthrox nicely complements, and will provide additional diversification to our existing analgesic product portfolio.  We look forward to making Penthrox available to health care professionals and the patients who would benefit from its use in appropriate settings."

Purdue Canada will pay MDI up to $3M CAD through a combination of upfront, milestone, and success based payments.

About Medical Developments International Ltd
MDI is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MDI is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox^®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, sports medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MDI is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Purdue Pharma Canada L.P.
Purdue Pharma Canada is a research-based pharmaceutical company with its headquarters, R&D operations, and manufacturing located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and central nervous system disorders (ADHD) with a growing pipeline of prescription and over the counter products. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma network of companies.

SOURCE Purdue Pharma

Medical Developments International: David Williams, Chairman, MDI, [phone]; John Sharman, Chief Executive Officer, MDI, [phone]; Purdue Pharma (Canada): Aimee Sulliman, Director of Communications, Pickering, Ontario, CANADA, Tel: [phone], Email: [email protected]